LB Pharmaceuticals expects Phase 3 NOVA-2 LB-102 schizophrenia topline data in H1 2027

LB Pharmaceuticals, Inc.

LB Pharmaceuticals, Inc.

LBRX

0.00
  • LB Pharmaceuticals pulled forward expected topline results from its Phase 3 NOVA-2 trial of LB-102 in schizophrenia to H1 2027.
  • Results have not been presented yet.
  • The timing shift reflects faster-than-expected enrollment in the pivotal, placebo-controlled study.
  • The company now targets a pre-NDA meeting with the FDA in H2 2027, contingent on the NOVA-2 readout.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-311357), on July 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.